Access to new medicines and safety checks on existing treatments will be jeopardized if politicians pick a new home for Europe’s London-based drugs regulator that is unacceptable to staff, its executive director told Reuters.

Picking Amsterdam, Barcelona or Vienna as the new headquarters of Europe’s drugs regulator after Brexit would be the best option for retaining staff, according to a survey of its workers.